Orforglipron vs Wegovy: Complete Oral GLP-1 Comparison (2026)
Orforglipron vs Wegovy: Complete Oral GLP-1 Comparison (2026)
Oral Wegovy is already available in the US. Orforglipron (Eli Lilly, $149/month) is awaiting FDA approval expected around April 2026 and would join it — giving patients a real choice between two oral GLP-1 pills. Orforglipron requires no fasting and no injection. Oral Wegovy (Novo Nordisk, $199–$299/month) delivers more weight loss in trials, but demands a daily 30-minute fasting window.
This is the comparison that will matter at the pharmacy counter in 2026. If you're asking "orforglipron vs wegovy which is better" or "is orforglipron worth it at $149/month," here's what the data already shows.
Editorial independence: Revenue does not influence our analysis. We compare these medications based on clinical data, pricing, and patient-relevant factors only.
Quick Comparison
| Factor | Orforglipron | Oral Wegovy |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Active ingredient | Orforglipron (small molecule) | Semaglutide (peptide) |
| Administration | Once-daily pill | Once-daily pill |
| Food restrictions | None — take anytime | Empty stomach, 30-min fast |
| FDA approved | Pending (expected April 2026) | Yes (2024) |
| Weight loss (trials) | 12.4% body weight (ACHIEVE-1, 40 wks) | 15.1% body weight (OASIS 1, 68 wks) |
| Primary side effect | Nausea (~59%) | Nausea + vomiting |
| Discontinuation rate | ~6% (ACHIEVE-1) | ~7% (OASIS 1) |
| Self-pay price | $149/mo (LillyDirect) | $199–$299/mo (Novo direct) |
| Medicare coverage | Obesity coverage pending | Obesity coverage pending |
| GoodRx subscription | Not available | ~$39/mo |
| Major PBM formularies | Yes (established) | Yes (established) |
Bottom line: Oral Wegovy wins on efficacy — roughly 2.7 percentage points more weight loss in clinical trials. Orforglipron wins on cost and daily convenience. The fasting requirement isn't minor: it's daily, permanent, and affects morning medications, coffee, and schedules.
How do orforglipron and oral Wegovy work differently?
The core difference: oral Wegovy is a peptide-based drug that requires food restrictions to survive stomach acid; orforglipron is a small-molecule compound that does not. Both activate the same GLP-1 receptor, but via structurally distinct pathways.
Orforglipron
Orforglipron is the first approved small-molecule, non-peptide GLP-1 receptor agonist. Unlike all other GLP-1 medications, it is not built from a peptide structure. This is why it can survive stomach acid without a protective fasting window — small molecules are absorbed differently than proteins.
Mechanism: activates GLP-1 receptors in the gut and brain, slowing gastric emptying, increasing satiety signaling, and reducing caloric intake. Once-daily oral dosing, titrated from a lower starting dose to 36mg maintenance.
Oral Wegovy (Semaglutide Pill)
Oral Wegovy contains semaglutide 25mg — the same active ingredient as injectable Wegovy and Ozempic, reformulated as a tablet using Novo Nordisk's SNAC absorption enhancer technology. Semaglutide is a peptide that mimics human GLP-1 and must be protected from stomach acid, hence the strict empty-stomach requirement.
Mechanism: same GLP-1 receptor activation pathway as orforglipron. Once-daily oral dosing, titrated over several months to the 25mg maintenance dose.
Why Oral Wegovy Produces More Weight Loss
Both drugs activate the same receptor — so why the gap? Several factors likely contribute:
- Trial duration: OASIS 1 ran 68 weeks; ACHIEVE-1 ran 40 weeks. More time at full dose generally means more weight loss.
- Pharmacokinetics: Semaglutide's established binding characteristics and half-life may produce more sustained receptor engagement.
- Dose optimization: Orforglipron is newer, and longer follow-up data may narrow the gap.
No published direct head-to-head trial between orforglipron and oral Wegovy exists as of April 2026. The 2.7% gap is real; its exact magnitude is harder to pin down without a direct comparison.
What does the evidence show for orforglipron vs oral Wegovy?
Important cross-trial caveat: These results come from separate Phase 3 programs with different durations, populations, and titration schedules. Do not treat these as a head-to-head comparison.
Orforglipron — ACHIEVE-1 (40 weeks, obesity indication)
| Metric | Orforglipron 36mg | Placebo |
|---|---|---|
| Mean weight loss | 12.4% | ~2% |
| Patients losing ≥5% | ~70% | ~25% |
| Patients losing ≥10% | ~47% | ~9% |
| Patients losing ≥15% | ~26% | ~3% |
Source: ACHIEVE-1 Phase 3 trial, 40 weeks.
Oral Wegovy — OASIS 1 (68 weeks, obesity indication)
| Metric | Oral Wegovy 25mg | Placebo |
|---|---|---|
| Mean weight loss | 15.1% | ~2.4% |
| Patients losing ≥5% | ~83% | ~26% |
| Patients losing ≥10% | ~63% | ~12% |
| Patients losing ≥15% | ~44% | ~6% |
Source: OASIS 1 Phase 3 trial, 68 weeks.
ACHIEVE-3: The Head-to-Head Note
ACHIEVE-3 compared orforglipron 36mg against oral semaglutide 14mg (Rybelsus/Ozempic tablet — the T2D formulation, not oral Wegovy's 25mg dose) in people with type 2 diabetes. Orforglipron beat that comparator on both A1C reduction and weight loss.
This is not the same as a head-to-head vs oral Wegovy. The 14mg semaglutide dose in ACHIEVE-3 is significantly lower than oral Wegovy's 25mg. Do not interpret ACHIEVE-3 as evidence that orforglipron outperforms oral Wegovy.
Does orforglipron require fasting like oral Wegovy?
No — orforglipron has no food restrictions and can be taken at any time. Oral Wegovy requires a 30-minute fasting window every morning, with no more than 4 oz of water, before eating or taking other medications. This difference matters daily for as long as you're on treatment.
This is the most patient-relevant daily-use differentiator between these two drugs.
Orforglipron: No restrictions
Take it any time of day. With breakfast, before bed, mid-afternoon. With coffee. With other medications. No fasting window, no water volume limit. If you miss a dose, take it whenever you remember.
Oral Wegovy: The 30-minute rule
- Take first thing in the morning on a completely empty stomach
- Swallow with no more than 4 oz (120 mL) of plain water
- Wait at least 30 minutes before eating, drinking coffee, juice, or any liquid other than water
- Wait 30 minutes before taking other oral medications
- Remain upright during the fasting window
This protocol is required every day for as long as you're on the medication. It is not a temporary induction phase.
Why does this matter clinically? Missed or inconsistent doses blunt real-world weight loss. The OASIS 1 trial controlled for adherence in ways that real-world use doesn't. Patients who struggle with the fasting requirement — because of morning medications, shift work, or simply not wanting to restructure their mornings — may see lower actual weight loss than the trial figures suggest.
Orforglipron's no-restriction dosing makes it easier to take consistently, which matters for real-world efficacy.
What are the side effects of orforglipron vs oral Wegovy?
| Side Effect | Orforglipron | Oral Wegovy |
|---|---|---|
| Nausea | ~59% | ~47% |
| Vomiting | ~14% | ~31% |
| Diarrhea | ~22% | ~20% |
| Constipation | ~14% | ~16% |
| Discontinuation (GI) | ~6% | ~7% |
GI symptoms are the primary concern for both medications, as expected for GLP-1 class drugs. The profiles differ:
- Orforglipron: Higher nausea rates (~59%), but lower vomiting and similar or better discontinuation. Nausea typically peaks during dose escalation and improves after stabilizing at maintenance dose.
- Oral Wegovy: Lower nausea rates (~47%) but significantly higher vomiting (~31%). The morning fasting protocol may also contribute to morning nausea on an empty stomach.
Neither medication causes dysesthesia (skin tingling/crawling) — that's a side effect associated with retatrutide, not these two drugs.
Thyroid/oncology class warning: Both carry the GLP-1 class warning about thyroid C-cell tumors observed in rodent studies. This has not been confirmed in humans, but remains a labeling requirement. Orforglipron's non-peptide structure is distinct from semaglutide, though both carry this class precaution.
Most GI side effects are transient, peak during titration, and resolve at maintenance dose. If symptoms are severe or persistent, your provider can slow the titration schedule.
How do orforglipron and oral Wegovy compare on price?
Orforglipron is cheaper: $149/month flat via LillyDirect vs. $199–$299/month for oral Wegovy. That's a $600–$1,800 annual difference at cash prices — though insurance can narrow or reverse that gap. Patients searching for the cheapest oral GLP-1 online will currently find orforglipron is the lowest-cost brand option.
| Orforglipron | Oral Wegovy | |
|---|---|---|
| LillyDirect / Novo Direct | $149/mo | $199–$299/mo |
| Medicare coverage | Obesity coverage pending | Obesity coverage pending |
| GoodRx subscription | Not available | ~$39/mo |
| Major PBM formularies | Yes (well-established, 14+ months) | Yes |
| Prior authorization | Common | Common |
| Novo/Lilly savings programs | LillyDirect baseline | NovoCare PAP, savings card |
Annual cash cost difference: Orforglipron saves $600–$1,800/year at list prices versus oral Wegovy ($149 vs $199–$299/month).
Insurance can reverse this math. Both orforglipron and oral Wegovy are now on major PBM formularies (Optum, CVS, Express Scripts). If your plan covers oral Wegovy at a low copay, that may undercut orforglipron's cash price advantage. Check your specific formulary and prior authorization requirements before choosing based on cost.
GoodRx subscription note: Oral Wegovy is available for ~$39/month through GoodRx Gold subscription — substantially below orforglipron's $149/month list price for patients who qualify. This is an important caveat for the cost comparison.
Medicare: Both drugs have $50/month bridge copay programs. Coverage on Part D varies by plan — verify with your specific plan before assuming either is covered.
Where can you get orforglipron and oral Wegovy?
Oral Wegovy is currently available through most major telehealth GLP-1 platforms. Orforglipron is awaiting FDA approval (PDUFA April 10, 2026) — once approved, it is expected to be available on most major platforms:
- Ro, GoodRx, LifeMD, Calibrate — oral Wegovy available now; orforglipron expected upon approval
- Hims — oral Wegovy (and other Wegovy products) only; Hims is an exclusive Novo Nordisk partner and does not prescribe orforglipron or any Eli Lilly medications
This matters: if you're already using Hims and want orforglipron once it's approved, you'll need a different platform.
Which should you choose: orforglipron or oral Wegovy?
There is no universally "right" answer between these two medications. Use this framework to identify which factors apply to you.
Choose Orforglipron If:
- Cost is a primary constraint. $149/month is meaningfully less than $199–$299/month, especially for patients paying out of pocket. Over a year, that's $600–$1,800 saved.
- The 30-minute fasting window won't work for your life. Morning medications, irregular schedules, shift work, or simply not wanting to restructure your mornings — orforglipron removes this daily friction permanently.
- You take other oral medications in the morning. Oral Wegovy's fasting restriction delays all other morning oral medications by 30 minutes. Orforglipron has no such limitation.
- You're already on LillyDirect for Zepbound. Single-platform management may be simpler.
- Blood sugar control is a priority (T2D). ACHIEVE-3 data shows orforglipron beat oral semaglutide 14mg on A1C reduction — consult your provider on the T2D indication.
Choose Oral Wegovy If:
- Maximum weight loss is your top priority. A 2.7 percentage point difference (15.1% vs 12.4%) is meaningful for patients with significant obesity-related health conditions where each additional percent of weight loss affects outcomes.
- Your insurance covers Wegovy at a low copay. If you're already approved for injectable Wegovy, the oral formulation may extend through the same PA pathway — and your copay may be lower than $149.
- You can access the GoodRx subscription rate (~$39/mo). This is significantly cheaper than orforglipron's list price.
- You're transitioning from injectable Wegovy. Same active ingredient; your provider can manage the formulation switch more predictably.
- You prefer Novo Nordisk's longer clinical track record. Semaglutide has been studied and prescribed since 2017 (as Ozempic). Orforglipron's real-world post-launch data is still accumulating.
Consider Injectable GLP-1 If:
- Either oral option hasn't produced adequate weight loss after full titration
- Your weight loss goal is ≥20% body weight — consider Wegovy HD (7.2mg injectable) or Zepbound
- You're following the CagriSema or retatrutide pipeline and want to reassess when those arrive
Pipeline Context
Two drugs on the horizon could change the oral GLP-1 comparison within 18–24 months:
- CagriSema (Novo Nordisk): Combination cagrilintide + semaglutide, 22.7% mean weight loss. NDA decision expected imminently.
- Retatrutide (Eli Lilly): Injectable triple agonist, 28.7% mean weight loss. NDA expected Q4 2026. Injectable, not oral.
Neither is available yet. Don't delay treatment on their account. See our CagriSema patient guide for timeline updates.
Frequently Asked Questions
Is orforglipron better than oral Wegovy?
Neither is universally better. Oral Wegovy produces more weight loss in trials (15.1% vs 12.4%). Orforglipron is cheaper and requires no fasting. Which is "better" depends on your weight loss goals, budget, insurance coverage, and whether the morning fasting protocol fits your life.
Are orforglipron and Wegovy the same kind of drug?
No. Both activate the GLP-1 receptor but are chemically unrelated. Orforglipron is a small-molecule non-peptide compound — the first of its kind to seek FDA approval for weight loss (PDUFA April 10, 2026). Wegovy contains semaglutide, a peptide-based molecule. The non-peptide structure is why orforglipron has no food restrictions.
Does orforglipron beat oral Wegovy in any trial?
ACHIEVE-3 showed orforglipron beat oral semaglutide 14mg (the T2D tablet dose) on A1C and weight in people with type 2 diabetes. This is not the same as beating oral Wegovy's 25mg dose. No head-to-head trial vs oral Wegovy has been published as of April 2026.
What's the real-world adherence difference?
Orforglipron shows approximately 70% 6-month persistence in post-launch data. Oral Wegovy's persistence data is less established at this stage. The no-fasting requirement may support better adherence for orforglipron in practice, though this hasn't been formally compared.
Can I switch between orforglipron and oral Wegovy?
Yes, with provider guidance. Both target the GLP-1 receptor, and pharmacological overlap means you should not take them simultaneously. If switching from oral Wegovy to orforglipron, your provider will re-titrate from a lower dose — don't assume you can start at the oral Wegovy maintenance equivalent.
Which platform should I use?
Most major telehealth GLP-1 platforms offer both. If you want orforglipron, avoid Hims — it is exclusively Novo Nordisk branded and does not prescribe Lilly medications. See our best oral GLP-1 options guide for current platform rankings.
Related Resources
- Orforglipron Complete Guide — Full clinical breakdown, trial data, and access details
- Oral Wegovy Pill Guide — Semaglutide 25mg pill: dosing, efficacy, and access
- Orforglipron vs Oral Wegovy (Head-to-Head Pill) — Focused pill-only comparison with deeper convenience analysis
- Best Oral GLP-1 Options 2026 — All oral GLP-1 medications ranked
- Cheapest GLP-1 Without Insurance (2026) — Full cost comparison across all options
- GLP-1 Dosing and Titration Schedules — What to expect during dose escalation
- Hims Weight Loss Review — Hims's Novo-only platform explained
- CagriSema Patient Guide — Next-generation pipeline context
Where to Get These Medications
Compare providers offering GLP-1 medications.
Related Guides
Does Medicare Cover Wegovy? Complete 2026 Coverage Guide
Medicare Part D is expanding Wegovy coverage for weight loss via the Bridge program (scheduled July 1, 2026). Here's what's expected, what you'll pay, how to qualify, and how to navigate prior authorization.
Read guide →Hims Wegovy: Everything About the Novo Nordisk Deal, Pricing & Transition
Complete guide to Hims' transition from compounded semaglutide to branded Wegovy through the Novo Nordisk partnership — pricing, timeline, what current patients should do.
Read guide →How to Get Orforglipron: Prescription Access, Telehealth, and What to Expect
Orforglipron (Eli Lilly's once-daily oral GLP-1) is now FDA-approved. Here's how to get a prescription through telehealth, which providers carry it, eligibility requirements, and cost.
Read guide →Oral Wegovy Pill: Complete Guide to the First GLP-1 Weight Loss Tablet
Everything you need to know about the oral Wegovy pill (semaglutide 25mg tablet) — FDA approval, dosing schedule, pricing, where to get it, and how it compares to injectable Wegovy.
Read guide →